Kantarjian et al53 assessed the efficacy and basic safety of dasatinib, as as opposed with imatinib, for the primary-line treatment method of CML-CP. 5 hundred and nineteen sufferers with newly diagnosed CML-CP ended up randomly assigned to receive dasatinib at a dose of a hundred mg at the time day-to-day (259 individuals) or imatinib in a dose of

Picked from data integrated with permission and copyrighted by Very first Databank, Inc. This copyrighted content has actually been downloaded from the certified knowledge company and isn't for distribution, other than as could possibly be approved because of the relevant conditions of use.inform your health care provider and pharmacist In case you